Gilteritinib
KMT2Ar
Kura Oncology, Inc.Small moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
9 Active assets in the KMT2Ar cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Kura Oncology, Inc. | Phase 1 | CC |
Venetoclax Kura Oncology, Inc. | Phase 1 | CC |
Azacitidine Kura Oncology, Inc. | Phase 1 | CC |
Ziftomenib Kura Oncology, Inc. | Phase 1 | CC |
Cytosin-Arabinosid Kura Oncology, Inc. | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Gilteritinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →